Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
Status:
Not yet recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerability of treatment with autologous tumor infiltrating
lymphocytes (TIL) administered via hepatic arterial infusion and preconditioning with
percutaneous hepatic perfusion in patients with liver metastases (but not restricted to) of
malignant melanoma